Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897406 | 0.84 | TP53 (0.57) | OPRL1TP53RECQLHTR2AHTR2C | |
| Charcoal, Activated SCHEMBL5897477 | 0.82 | TP53 (0.55) | OPRL1TP53RECQLHTR2AHTR2C | |
| SCHEMBL3784740 | 0.80 | TP53 (0.53) | OPRL1TP53RECQLHTR2AHTR2C | |
| SCHEMBL3789653 | 0.80 | TP53 (0.53) | OPRL1TP53RECQLHTR2AHTR2C | |
| SCHEMBL2316090 | 0.78 | TP53 (0.52) | OPRL1TP53RECQLADRA1AADRA1D | |
| Cyanide SCHEMBL27463529 | 0.78 | TP53 (0.52) | OPRL1TP53RECQLHTR2AHTR2C | |
| SCHEMBL14685880 | 0.77 | TP53 (0.47) | OPRL1TP53RECQLHTR2AHTR2C | |
| SCHEMBL4065015 | 0.77 | TP53 (0.50) | OPRL1TP53RECQLHTR2AHTR2C | |
| SCHEMBL23974476 | 0.76 | OPRL1 (1.00) | OPRL1 | |
| SCHEMBL16233612 | 0.75 | TP53 (0.48) | OPRL1TP53RECQLHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | claimed |
| CN-118206514-A | Reaction method for preparing olefin by deacylation of visible light induced ketone | 国科大杭州高等研究院 | 2024-06-18 | — | — | CN | disclosed |
| US-9981910-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-05-29 | — | — | US | disclosed |
| CN-105669688-A | Method for preparing hexahydropyrano-pyrimidone derivative by Br nsted acid ion liquid catalysis | 安徽工业大学 | 2016-06-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | OPRL1 1057/4885TP53 2656/4885RECQL 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.